NCT00782535已完成2 期
EVALUATION OF THE SAFETY AND EFFICACY OF TREATMENT WITH SINGLE DOSES OF CHF 4226 pMDI IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE A Multicenter, Randomized, Double-Blind,Placebo-Controlled, 5-Way Crossover Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 5
- 主要终点
- FEV1
研究概览
简要总结
The purpose of this study is to characterize the dose-response profile of peak and trough FEV1 after single dose administrations of carmoterol in patients with COPD.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 40 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient has signed an IRB approved Informed Consent form and the written informed consent was obtained prior to any study-related procedure(s)
- •Patient is a male or non-pregnant female, 40 -75 years old, inclusive
- •Patient has a current or past cigarette smoking history of at least 15 pack-years
- •Patient has a clinical diagnosis of COPD in accordance with the recommendations of the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO) Global Initiative for Chronic Obstructive Lung Disease (GOLD)
- •Patient meets the following requirements after an FEV1 albuterol reversibility test (i.e., 30 minutes following 400µg (metered dose) albuterol MDI):
- •FEV1/FVC < 70%
- •FEV1 is at least 0.9L
- •FEV1 30% - 80%, inclusive, of patient's predicted normal value
- •∆FEV1 > 5% of pre-albuterol value
- •If ∆FEV1 </= 5% of pre-albuterol value, then this requirement must be met after retesting during the run-in period, at least 24 hours prior to Visit 2.
排除标准
- •Patient has a history of asthma
- •Patient has a blood eosinophil count > 500/µL
- •Patient has a history of allergic rhinitis or atopy
- •Patient had a COPD exacerbation or a lower respiratory tract infection within 8 weeks prior to screening, or during the run-in period, that resulted in the use of an antibiotic, or oral or parenteral corticosteroids
- •Patient is on an inhaled corticosteroid that has been initiated, or the effective dose has been changed, within 4 weeks prior to screening or during the run-in period
- •Patient has an uncontrolled cardiovascular (e.g., uncontrolled hypertension), respiratory, hematologic, immunologic, renal, neurologic, hepatic, endocrine (e.g., uncontrolled diabetes mellitus) or other disease, or any condition that might, in the judgment of the Investigator, place the patient at undue risk or potentially compromise the results or interpretation of the study
- •Patient has clinically significant abnormal routine hematology (e.g., anemia) and/or clinical chemistry value(s).
- •Patient has a history of coronary artery disease, cerebrovascular disease, cardiac arrhythmias
- •Patient has lung cancer or a history of lung cancer
- •Patient has active cancer or a history of cancer with less than 5 years disease free survival time (whether or not there is evidence of local recurrence or metastases). Localized basal cell carcinoma (without metastases) of the skin is acceptable.
- •Patient has a serum potassium value ≤ 3.5 mEq/L or > 5.5mEq/L and/or a fasting serum glucose value ≥ 140 mg/dL
- •Patient has an abnormal QTcF interval value in the Screening visit ECG test (i.e., > 450 msec in males or > 470 msec in females)
- •Patient has developed Cor Pulmonale
- •Patient is receiving long term oxygen therapy, i.e., > 16 hours/24-hour period, every day, unless residing at an elevation > 4000ft
- •Patient has used any of the following medications prior to Screening and has not met the specified minimum washout period:
- •Long acting anti-cholinergic agent (i.e., tiotropium): 7 days
- •Short acting anti-cholinergics: 8 hours
- •Fixed combinations of β2-agonists and inhaled corticosteroids: 48 hours
- •Fixed combinations of an anti-cholinergic and short acting β2-agonist: 8 hours
- •Long-acting β2-agonists: 48 hours
- •Short acting β2-agonists: 6 hours
- •Theophylline and other xanthines: 1 week
- •Parenteral or oral corticosteroids: 1 month
- •Patient has taken any non-permitted medication
- •Patient has received a live-attenuated virus vaccination within two weeks prior to screening or during the run-in (inactivated Influenza vaccination is acceptable provided it is not administered within 48 hours prior to Screening)
- •Patient has a known intolerance/hypersensitivity to β2-adrenergic agonists, propellant gases/excipients
- •Patient is pregnant or lactating female, or female physiologically capable of becoming pregnant UNLESS they meet the following definition of post-menopausal: 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels > 40 mIU/mL OR are using one or more of the following acceptable methods of contraception:
- •surgical sterilization (e.g., bilateral tubal ligation, hysterectomy)
- •hormonal contraception (implantable, patch, oral)
- •double-barrier methods (any double combination of: IUD, male or female condom with spermicidal gel, diaphragm, sponge, cervical cap)
- •Patient is male and does not agree to use a medically acceptable contraceptive (abstain from sexual intercourse, or use a condom with spermicide), or has not had a vasectomy at least 6 months prior to study participation, unless their sexual partner is not of child-bearing potential
- •Patient is mentally or legally incapacitated
- •Patient has participated in another investigational study within 30 days prior to screening
- •Patient abuses alcohol or other substances
- •Patient does not maintain regular day/night, waking/sleeping cycles (e.g., night shift worker)
- •Patient is potentially non-compliant or unable to perform required outcome measurements of the protocol
研究组 & 干预措施
Treatment B
Experimental
Single therapeutic dose of CHF 4226 pMDI
干预措施: CHF 4226 pMDI (Drug)
Treatment A
Experimental
Single therapeutic dose of CHF 4226 pMDI
干预措施: CHF 4226 pMDI (Drug)
Treatment C
Experimental
Single supratherapeutic dose of CHF 4226 pMDI
干预措施: CHF 4226 pMDI (Drug)
Treatment D
Experimental
Single supratherapeutic dose of CHF 4226 pMDI
干预措施: CHF 4226 pMDI (Drug)
Treatment E
Placebo Comparator
Single dose of placebo
干预措施: Placebo (Drug)
结局指标
主要结局
FEV1
时间窗: T-1hr, T-10min, and 15 and 30 minutes, 1, 2, 3, 23 and 24 hours for each treatment period
次要结局
- FVC(T-1hr, T-10min, and 15 and 30 minutes, 1, 2, 3, 23 and 24 hours for each treatment period)
- serum glucose(pre dose and 1, 4, 6 and 24 hrs post dose for each treatment period)
- serum potassium(pre dose and 1, 4, 6 and 24 hrs post dose for each treatment period)
- plasma concentrations of CHF 4226(pre dose and 15 minutes and 2 hours post dose for each treatment period)
- urinary excretion of CHF 4226(pre dose and 0-24 hrs post dose for each treatment period)
研究者
研究点 (5)
Loading locations...
相似试验
Unknown
2 期
Efficacy of the Dose Regimen of Oral Vitamin D 50,000 IU in the Treatment of Vitamin D DeficiencyVitamin D DeficiencyNCT02192229Hayat Pharmaceutical Co. PLC80
已完成
1 期
A Study to Evaluate the Safety, Tolerability, and Drug Levels of MYK-224 Administered in Single and Multiple Doses in Healthy Adult Japanese ParticipantsHealthy VolunteersNCT05405543Bristol-Myers Squibb36
已完成
1 期
An A/B Dose Escalation Study of AbGn-7 Alone and With FOLFOX7 Treatment in Patients With Advanced Solid TumorsSolid Tumor of Epithelial OriginGastric CancerNCT01466569AbGenomics B.V Taiwan Branch13
已完成
1 期
A Study of PLX2853 in Advanced Malignancies.Uveal MelanomaNon-Hodgkin LymphomaAdvanced MalignanciesSolid TumorDiffuse Large B Cell LymphomaSmall Cell Lung CancerFollicular LymphomaOvarian Clear Cell CarcinomaNCT03297424Opna Bio LLC49
进行中（未招募）
不适用
Assessment of Efficacy and Safety of Olmesartan Medoxomil in Children and Adolescent Patients With High Blood PressureHypertensionEUCTR2015-003329-32-Outside-EU/EEADaiichi Sankyo Pharma Development362